ArticleCureus2026
Adjunctive Nutritional Supplementation in Drug-Resistant Epilepsy: A Prospective Observational Study Evaluating Quality of Life and Seizure Outcomes.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDrug-resistant or refractory epilepsy remains a significant clinical challenge, with persistent seizures and impaired quality of life, despite optimized antiepileptic therapy. Increasing attention has been directed toward adjunctive nutritional strategies that may support neuronal stability and overall well-being. The aim of the present study was to evaluate the real-world impact of Epregres Unique 12 as an adjunct to standard antiepileptic drug therapy on the quality of life and seizure frequency in patients with drug-resistant epilepsy. MATERIALS AND
methodsThis prospective observational study was conducted at a tertiary care center between January 2023 and December 2024. Twenty-six patients with drug-resistant epilepsy were followed for 12 weeks after the initiation of adjunctive nutritional supplementation. Antiepileptic drug regimens were continued without protocol-driven modifications. The quality of life was assessed using the Quality of Life in Epilepsy-31 (QOLIE-31) questionnaire at baseline and after 12 weeks. Seizure frequency was documented by using patient-maintained seizure diaries. Data were analyzed using paired statistical tests with effect size estimation.
resultsTwenty-six patients (19 males, seven females; mean age 37.2 ± 7.4 years) were included. Emotional well-being showed a statistically significant improvement at 12 weeks (p = 0.009) with a moderate effect size. The total QOLIE-31 score demonstrated a clinically meaningful improvement, approaching statistical significance (p = 0.061). Seizure frequency decreased in 20 (76.9%) patients, including complete seizure cessation in 6 (23.1%) patients. The supplement was well-tolerated, with only one minor adverse event reported.
conclusionAdjunctive nutritional supplementation is associated with improvements in emotional well-being and favorable trends in quality of life and seizure frequency in patients with drug-resistant epilepsy. While these findings are encouraging, controlled studies with larger sample sizes are required to confirm these observations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.